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Respiratory Syncytial Virus (RSV) is the commonest cause of severe respiratory infection
in infants, leading to over 3 million hospitalizations and around 66,000 deaths worldwide
each year. RSV bronchiolitis predominantly strikes apparently healthy infants, with age as
the principal risk factor for severe disease. The differences in the immune response to
RSV in the very young are likely to be key to determining the clinical outcome of this
common infection. Remarkable age-related differences in innate cytokine responses fol-
low recognition of RSV by numerous pattern recognition receptors, and the importance
of this early response is supported by polymorphisms in many early innate genes, which
associate with bronchiolitis. In the absence of strong,Th1 polarizing signals, infants develop
T cell responses that can be biased away from protective Th1 and cytotoxic T cell immu-
nity toward dysregulated, Th2 and Th17 polarization. This may contribute not only to the
initial inflammation in bronchiolitis, but also to the long-term increased risk of developing
wheeze and asthma later in life. An early-life vaccine for RSV will need to overcome the diffi-
culties of generating a protective response in infants, and the proven risks associated with
generating an inappropriate response. Infantile T follicular helper and B cell responses are
immature, but maternal antibodies can afford some protection.Thus, maternal vaccination
is a promising alternative approach. However, even in adults adaptive immunity following
natural infection is poorly protective, allowing re-infection even with the same strain of
RSV. This gives us few clues as to how effective vaccination could be achieved. Challenges
remain in understanding how respiratory immunity matures with age, and the external
factors influencing its development. Determining why some infants develop bronchiolitis
should lead to new therapies to lessen the clinical impact of RSV and aid the rational design
of protective vaccines.
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INTRODUCTION
Respiratory syncytial virus (RSV) was first isolated in 1956 from
a captive chimpanzee (1). Initially named Chimpanzee Coryza
Agent, RSV was soon recovered from infants with lower respiratory
illness and identified as a human pathogen (2). Almost six decades
later, it remains the commonest viral cause of serious respiratory
illness in children under 5 years of age and the major cause of
infantile bronchiolitis. RSV is estimated to cause 3.4 million hos-
pitalizations and at least 66,000 deaths worldwide each year (3, 4),
but since 99% of these deaths occur in developing countries, this
is likely to be an underestimate. Immunity to reinfection with a
single strain of RSV is, at best, partial; re-infections with antigeni-
cally similar strains occur throughout life and through to old age.
The continued lack of any specific treatment or a safe and effective
vaccine indicates the vital importance of better understanding of
immunity to RSV infection in making progress in reducing global
mortality and morbidity from RSV infection.
VIRUS
Respiratory syncytial virus, of the family Paramyxoviridae, order
Mononegavirales, is an enveloped, non-segmented negative-strand
RNA virus (Figure 1). One of the more complex members of the
Paramyxoviridae family, its 15.2 kb genome comprises 10 genes
in the order 3′-NS1-NS2-N-P-M-SH-G-F-M2-L-5′. These encode
a total of 11 proteins, as the M2 mRNA contains two overlap-
ping open reading frames resulting in two polypeptides, M2-1
and M2-2. The two major surface proteins of RSV, the F and highly
glycosylated G-protein are believed to be the major targets of the
antibody response. Antisera to RSV show extensive cross-reactivity
to natural strains, but two major antigenic subgroups have been
defined [A and B; (5)]. The relative antigenic stability of RSV
makes the apparent lack of effective immunological memory all
the more intriguing. Infection is normally confined to the respira-
tory mucosa and does not usually disseminate to other organs or
appear in the blood.
CLINICAL DISEASE AND TREATMENT
By the age of two, over 80% of children have experienced at least
one RSV infection, 2/3 of these occurring in the first year of life
(8). Whilst the majority of infants display only mild upper respi-
ratory tract infection (URTI) or occasionally otitis media, around
one-third will develop an infection of the lower respiratory tract
(LRTI), usually bronchiolitis. This is caused by an infiltration of
inflammatory cells into the airspaces, mucus hyper-production,
shedding of necrotic airway epithelial cells, and edema of the air-
way wall. These processes lead to a narrowing of the airway lumen,
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FIGURE 1 |The structure of RSV. The 15.2 kb negative sense, single
stranded RNA RSV genome consisting of 10 genes, encoding 11 proteins,
and below, an illustration of a filamentous virus particle; one of the
predominant forms, which bud from the infected cell. The outer envelope
contains the heavily glycosylated surface glycoprotein G and the fusion (F)
and SH proteins. The matrix protein lies within the membrane, surrounding
the ribonucleoprotein complex, consisting of the genome associated with
N, P, and the large RNA-dependent RNA polymerase (L) protein [based on
(6) and (7)].
airflow obstruction, overinflation, and impaired gas exchange. In
more severe RSV disease crackles and wheeze occur with labored
breathing, tachypnea, and hypoxia (9). In children under 5 years of
age, around 10% of those with RSV LRTI require hospitalization
(3). The peak of admissions in the UK occurs at approximately
1 month of age (10). In addition to the enormous pediatric bur-
den, RSV is increasingly recognized as an important pathogen of
the elderly, causing a mortality rate approaching that of influenza
A in the over-65s (11, 12).
Palivizumab (Synagis) is a humanized monoclonal antibody
against the F protein of RSV. It is given prophylactically to infants
at high risk and protects against severe disease (13), but has no
benefit in those with active infection. The anti-viral drug ribavirin
is of limited efficacy (14).
RISK FACTORS
One of the key unanswered questions is why some unfortunate
infants develop severe bronchiolitis, while most suffer mild URTI
or LRTI. Many risk factors have been defined including prema-
turity, low birth weight, male sex, low socio-economic status, and
pre-existing medical conditions such as congenital heart disease
and immunodeficiency (4, 15). HIV infection is associated with
increased risk of RSV LRTI and poor outcome, and in such chil-
dren seasonal peaks of RSV infection are less evident. This may
in part explain the large disease burden in areas of high HIV-
prevalence (16, 17). Despite the known predictors of severe disease,
the majority of infants hospitalized with RSV bronchiolitis are pre-
viously healthy and without known risk factors other than young
age, the biggest risk factor for severe bronchiolitis (4, 10, 18, 19).
It is likely that maternal factors may influence the developing
lungs and immune system of the fetus. Maternal smoking and diet
are independent risk factors for the development of bronchiolitis
(20, 21) and low cord blood vitamin D in otherwise healthy infants
is associated with a sixfold increased risk of developing RSV LRTI
in the first year of life (22) consistent with a linkage of bronchioli-
tis with polymorphisms in the vitamin D receptor (23). In utero
influences on infant immune responses and the outcome of RSV
infection is an area that deserves further study.
Around 20% of the susceptibility to severe RSV has been attrib-
uted to genetic factors (24) and numerous genetic polymorphisms
in immune genes have been reported. These include variants in
the 5q31 Th2 cytokine locus (25), IL-8 (26), and IL-4-Rα (27,
28). A large cohort study found that single nucleotide polymor-
phisms in genes of the innate immune system were particularly
associated with hospitalization with bronchiolitis (23). A small
number of genes were found to be differentially expressed in cord
blood from infants who went on to be hospitalized with RSV ver-
sus those that experienced a mild infection, including TNFRSF25,
which is involved in activation of NF-κB (29). Consistent with
this, NFKBIA promoter variants which increase toll-like receptor
(TLR)-mediated inflammatory cytokine production are associated
with severe RSV bronchiolitis and AHR in children with RSV in
the first year of life (30). Together this suggests that the immune
response to RSV is key to determining the outcome of infection in
the very young (Figure 2).
IMMUNE RESPONSE TO RSV INFECTION
It is difficult to overcome the ethical and practical problems asso-
ciated with studying immune responses in neonates, especially in a
transient self-limiting disease from which full recovery is the rule.
We therefore have relatively little knowledge of what the normal
infantile immune response to RSV comprises, especially at the site
of disease rather than in peripheral blood. Instead, much of the
information available comes from animal studies, clinical stud-
ies in adults, or very severe or fatal cases of infection in babies,
often with the complications of comorbidities such as bacterial
superinfection. Histopathological analysis suggests that the virus
predominantly infects the superficial ciliated cells of the upper air-
way, the epithelium of the small bronchioles and type-I alveolar
pneumocytes (31). The fact that the virus completes it life cycle in
superficial airway cells may aid its immune evasion, since systemic
immunity normally gains little access to the epithelium.
The exact contributions of virus and host to the pathogenesis of
bronchiolitis remain contentious. Histological studies show a pro-
nounced inflammatory infiltrate in bronchiolitis and animal mod-
els support a role for immune mediated pathology to RSV (31–33).
However, others report that severe disease is associated with a high
viral load and relative lack of lymphocytes in the lungs (34).
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FIGURE 2 |The neonatal immune response to RSV infection. Maternal
antibody can reduce the burden of RSV infection in infants. Once infection is
established, the innate immune response produces reduced levels of antiviral
cytokines, such as interferons. In infants, reduced signaling from TLRs and
altered antigen presenting cell function, including low IL-12 and enhanced
production of IL-6 and IL-23, coupled with a reduced activation of regulatory T
cells, may result in an adaptive response that is skewed toward Th2 and Th17
and away from protective Th1 and CTL. Impaired Tfh activation, coupled with
little or no B cell memory and inhibition of antibody production by IFNγ,
produces low titer, low affinity antibody. The result may be a poorly protective
and dysregulated immune response that leads to bronchiolitis in susceptible
infants.
DETECTION OF THE VIRUS AND THE EARLY INNATE
RESPONSE
Adaptive immune responses have been the focus of the ongoing
quest for vaccines. However, most of the SNPs linked to infant RSV
bronchiolitis identify the critical importance of the innate immune
system (23), indicating that this early response to the virus could
have important consequences for the outcome of the infection.
Early viral detection is mediated through pattern recognition
receptors (PRRs) expressed by epithelial cells, fibroblasts, and anti-
gen presenting cells (APCs) of the respiratory tract. Their ligation
results in activation of NF-κB and the interferon regulatory fac-
tor (IRF) family members, leading to upregulated expression of
cytokines, chemokines, and anti-viral factors. PRRs known to
be important for recognition of RSV are TLR-4, TLR3, TLR2/6,
TLR7/8, and RIG-I [reviewed (35, 36)].
The first PRR to be implicated in the response to RSV was
TLR-4. Kurt-Jones and colleagues demonstrated in vitro that the
F protein could trigger IL-6 production from human PBMCs,
dependent on TLR-4/CD14 engagement (37). The same group
showed impaired viral clearance and natural killer (NK) cell
responses in a Tlr4 knock-out mouse, suggesting a protective
in vivo role of TLR-4 in RSV infection (38). In humans, there
are two common missense mutations in the Tlr4 gene, associated
with hyporesponsiveness to intranasal LPS (39, 40). Both of these
polymorphisms have subsequently been linked to increased risk
of severe RSV bronchiolitis in infants (41), and in vitro cytokine
production was blunted in PMBCs and human bronchial epithe-
lial cells exposed to RSV if they expressed these TLR-4 alleles (42).
This genetic association with severe RSV disease was not con-
firmed by Paulus et al. (43), and another study found associations
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only when their cohort was divided into cases from two different
RSV epidemics (44). Thus, it may be that particular RSV strains
and TLR-4 phenotypes can combine to influence risk of severe
bronchiolitis.
Initial detection of RSV is also mediated by TLR3, which is
expressed intracellularly and recognizes dsRNA present during
RSV replication. In contrast to the Tlr4 knock-out model, Tlr3
knock-out mice can still clear RSV effectively; however, they dis-
play goblet cell hyperplasia with mucus over-production (45),
which in the infantile lung could result in a more severe disease
phenotype given the narrow lumens of the immature respiratory
tract. Knocking out TLR7, which along with TLR8 detects ssRNA,
also resulted in exacerbated mucus production in a mouse model
(46). Interestingly, the lack of TLR7 seemed to skew the RSV T cell
response toward Th17, which is associated with immunopathology
in human infants (see below).
Given the exacerbated pathology seen in animal models lack-
ing particular PRRs, it is tempting to relate these findings to
immaturities in human neonatal PRR responses. In stimulation
assays of cord blood versus adult blood cells using TLR ligands,
Kollmann et al. reported qualitative and quantitative differences
in the responses of adults and neonates, with neonatal mono-
cytes producing more Th17-skewing cytokines (47). Another
recent study found neonatal blood contained a lower proportion
of TLR-4hi CD14+ CD16+ monocytes, leading to lower over-
all blood TLR-4 expression (48). Since TLR responses appear to
be important for determining the outcome of an RSV infection,
these age-dependent differences could help to explain the striking
susceptibility of the very young to severe RSV disease.
Although these studies of cord blood are informative, the innate
immune system of the lung is likely to be different in many critical
aspects to that of the systemic immune system. We currently know
remarkably little about how innate pulmonary immunity matures
with age and the factors influencing it. This is partly because of
the difficulty of accessing structural lung cells in children with
bronchiolitis and healthy controls. Extensive epithelial sloughing
is associated with severe RSV disease and as the primary site of
replication of RSV the respiratory epithelium is thought to be
an important early source of cytokines. We are just beginning to
understand how the respiratory epithelium differs in infants and
how it responds to viral infection (49). Recent studies of well dif-
ferentiated primary pediatric nasal and bronchial epithelial cells
have demonstrated viral growth and shedding in these cells and
found that the extent of epithelial production of cytokines and
mucus and epithelial apoptosis differs with viral strains (50–53).
Importantly, responses in nasally derived epithelial cells were sim-
ilar to those from the lower airways, suggesting that these may be
a more easily accessible source of respiratory epithelial cells with
which to study responses to RSV in infants.
Once the immune system detects the presence of virus, produc-
tion of pro-inflammatory cytokines and chemokines is initiated.
This leads to a positive feedback loop whereby cells recruited
into the airways contribute to mediator production. For exam-
ple, high concentrations of the pro-inflammatory cytokines IL-6
and TNF-α are present in the bronchoalveolar lavage (BAL) fluid
from infants with RSV bronchiolitis (54) and the production
of chemokines such as CXCL10 (IP-10), CXCL8 (IL-8), CCL2
(MCP1), CCL3 (MIP-1α), and CCL5 (RANTES) has also been
demonstrated (55).
In the early stages of bronchiolitis, it is thought that neutrophils
are the major recruited leukocyte to both the upper and lower air-
way (56, 57). Whether this significant neutrophilia is pathogenic
or protective is debated – whilst neutrophils can destroy infected
cells, they can also release enzymes that damage surrounding tis-
sue. A genetic polymorphism in the IL-8 promoter region, linked
to augmented IL-8 production on whole-blood LPS stimulation,
has been associated with increased risk of severe RSV disease
in infants, implicating this potent neutrophil chemoattractant in
pathogenesis (26). Increased levels of IL-8 have been detected in
the nasal lavage of infants hospitalized with RSV-positive com-
pared to RSV-negative respiratory illnesses (58). In a recent study,
Mella et al. also found higher levels of IL-8 and IL-6 in the serum
of infants hospitalized with RSV compared to healthy controls;
however, when blood was stimulated in vitro, the production of
these cytokines negatively correlated with disease severity (59). It
is not clear whether neutrophilia is also seen in common milder
cases of bronchiolitis.
In the early response to viral infection, another key set of
inflammatory mediators to be induced is the interferon (IFN)
family. Type-I IFNs (IFN-α and IFN-β) act on the IFNAR receptor,
found on all cell types, to induce an anti-viral state in the cell. One
way in which RSV may subvert effective viral clearance is via its
NS1 and 2 proteins, which inhibit IFN-α/β signaling, suggesting
that a more powerful innate IFN response would be detrimental
to viral survival (60–65). Indeed, type-I IFN signaling profoundly
influences the outcome of RSV infection in animal models, and
mice lacking IFNAR show increased viral load but decreased pro-
duction of pro-inflammatory cytokines, implying that type-I IFNs
are important players in initiation of the innate response (66, 67).
Plasmacytoid dendritic cells (pDCs), are potent producers of IFN-
α/β. These cells are mobilized, along with myeloid DCs, to the
nasal mucosa during RSV infection (68) and according to murine
studies are important for both clearance of the virus and avoid-
ance of excessive immunopathology (69, 70). However, in neonatal
cord blood, pDCs have been shown to be deficient in their ability
to produce IFN-α in response to RSV, which could potentiate the
risk of LRTI in early-life (71).
Mouse models have allowed study of lung-resident DCs and
the identification of immaturities of lung dendritic cells in the
neonatal response to RSV. Ruckwardt and colleagues reported an
imbalance in the subsets of two lung-resident DCs in neonatally
infected mice, with an increased ratio of CD103+:CD11c+ cells
found in the draining lymph nodes. These neonatal DCs also
expressed lower levels of co-stimulatory molecules and were less
able to process and transport antigen (72). Coupled with an ability
of the RSV NS1/2 proteins to inhibit DC maturation (probably via
the IFN antagonism already described) (73), RSV appears particu-
larly well-equipped in an already immature host to avoid effective
antigen presentation and to alter subsequent T cell priming.
Natural killer cells are also an important part of the early
immune response according to the murine model, providing an
early source of IFN-γ to help activate DCs and prime the T cell
response, and via direct cytotoxic destruction of infected cells (74,
75). Again, the contribution of these cells to protection versus
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immunopathology is debateable. In infants, severe RSV bronchi-
olitis has been associated with low NK cell numbers in the lung
and the peripheral blood, suggesting a protective effect (34, 76).
Low levels of NK cells might also be due to the fact that G-protein
of RSV is able to compete with fractalkine, one of the chemokines
that attracts these cells, for its receptor (CX3CR1) (77). From stud-
ies on cord blood, neonatal NK cells are thought to be immature,
expressing lower levels of certain inhibitory and activating recep-
tors and of IFN-γ (78). In animal models, NK cells in the BAL
peak at day 3 post-RSV infection (79), and appear to be vital for
development of an“appropriate”T cell response (discussed below)
and the avoidance of Th2-skewing and allergic sensitization (74).
ADAPTIVE IMMUNITY TO RSV AND VACCINATION
Natural infection gives us few clues about adaptive protection
against RSV. Following infection, protection generated is short-
lived and incomplete, allowing RSV to re-infect the host through-
out life (80). Indeed, it is possible, experimentally, to repeatedly
re-infect an individual with an identical RSV strain (81). Most nat-
ural re-infections occur with genetically different strains, although
whether this is due to the host immune response and infection his-
tory, or whether this simply reflects changes in circulating virus, is
unclear. Recent longitudinal studies of RSV infections in children
over a number of RSV seasons established that children can be
naturally re-infected with the same strain of virus even within the
same cold season (82), although the rate of a second RSV infection
is reduced for 6 months (83) and the duration of viral shedding
is reduced (84), suggesting some generation of partially protec-
tive immunity in infants following natural infection. The fact that
dominant circulating strains of RSV are replaced in successive epi-
demics suggests the existence of some strain-specific immunity at
a population level that is sufficient to confer a competitive advan-
tage on a new strain. An outstanding question is whether infants
develop more severe disease because of the immaturity of their
immune system or because they are undergoing a primary infec-
tion. Severe disease is evident in children undergoing a secondary
RSV infection at a young age (82, 83) suggesting that immunity
generated after natural infection does not confer protection against
severe disease and that age, rather than experience of infection, is
the most important factor in disease severity.
B CELL RESPONSE TO RSV INFECTION
The remarkable effectiveness of palivizumab prophylaxis shows
that neutralizing antibody of sufficiently high affinity and titer is
sufficient to confer protection of the lower airway. What is less
clear is why antibody produced after natural infection is poorly
protective against reinfection. In adults, the highest titers of nat-
urally occurring pre-existing serum neutralizing IgG and nasal
IgA correlate with protection against naturally acquired infection
(85, 86), and with protection in re-challenge studies (81). Further,
those with the highest levels of neutralizing antibody tend to be
protected against RSV-associated LRTI and hospitalization (87),
but in most adults antibody titers are below the levels needed to
achieve full airway protection despite a lifetime of repeated infec-
tion. It is possible that a high antibody titer is simply indicative
of recent infection and that it is a surrogate marker of some other
response that is protective.
In humans, IgG antibody to RSV is passed from the mother
to the infant via the placenta and colostrum and in the first few
months of life the majority of antibody present in the neona-
tal serum will be maternal IgG. A study of a large birth cohort
in Kenya demonstrated that 97% of infants had RSV-specific anti-
body from their mothers,but this declines rapidly with a half-life of
2–3 months (88, 89). The titer of maternal antibody correlates with
protection against infection, severe disease, and hospitalization
(83, 88, 90–92).
VACCINATION TO GENERATE PROTECTIVE ANTIBODY RESPONSES
Following a disastrous trial of formalin-inactivated-RSV (FI-RSV)
vaccine in the 1960s, research into the development of an RSV vac-
cine has proceeded cautiously and no vaccine for RSV has yet been
licensed (93–95). Children who had received the FI-RSV vaccine
had a far higher incidence of severe disease, and two died, as a
consequence of natural RSV infection following vaccination. The
most significant incidence of enhanced disease occurred in the
youngest infants, which may indicate that the immaturity of the
infant immune system or the lack of previous experience of infec-
tion contributed to the vaccine enhanced illness. As these vaccine
trials occurred over 50 years ago, we are not able to precisely eluci-
date what went wrong, but the mouse and primate models largely
recapitulate the eosinophilic inflammation, which was reported in
the post-mortem examination of the fatal cases. The antibodies
induced in vaccinated children were poorly neutralizing and for-
mation of immune complexes and local complement activation in
the lungs may have promoted pathology (96, 97). Although they
may not entirely recapitulate the clinical situation in the original
trials (98), studies in mice have suggested reasons for the poor
quality of the antibody response, including modification of viral
proteins by the formalin treatment (99) and the lack of a strong
TLR stimulus in FI-RSV (100). Further, they have shown the regu-
latory T cell response following FI-RSV vaccination and infection
is defective (101). Thus properties of the FI-RSV preparation com-
bined with the immature infant immune system led to devastating
results.
Maternal vaccination to induce sufficiently high titer of anti-
body could be a safe and effective strategy to delay infection
and protect against severe disease within the first few months of
life. A small scale randomized, double-blind, placebo controlled
study of healthy women immunized during the third trimester of
pregnancy demonstrated that maternal vaccination could boost
antibody titers of RSV in the mother and infants, with no apparent
adverse effects (102).
Infants are vulnerable to RSV infection once maternal antibody
has waned and so those 4 months old and above are important
candidates for the development of an effective vaccine (4, 98, 103)
and a number of promising vaccine candidates are being devel-
oped by pharmaceutical companies (104). Most research into the
development of an RSV vaccine has focused on the generation of
protective antibodies. In particular, research has centered on gen-
erating antibodies to the pre-fusion conformation of the F protein,
the structural form present on the surface of the free virus particle,
which contains unique antigenic sites recognized by neutralizing
antibodies [(105) and (106)]. Neonates can generate their own
antibody response following RSV infection, although this is low
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or absent in the youngest children (107–109). In autopsy samples
of infants who had died of bronchiolitis, large numbers of infil-
trating IgA, IgG, and IgM secreting B cells were found in the lungs
(109). In bronchiolitis, the local nasal IgA and IgM response, but
not IgG, and production of the B cell tropic factor APRIL, cor-
relate with better oxygen saturation, suggesting a protective role
for local secreted antibody (109). Interestingly, the repertoire of
V-gene segments used by young infants<3 months of age to gen-
erate RSV-specific antibodies is biased compared to those used in
adults, with fewer somatic mutations, and this may account for the
poor functional quality of the antibody response at this age (110).
Any neonatal RSV vaccine will have to overcome the limitations
of the neonatal antibody response to produce an antibody of suf-
ficiently high quantity and quality to prevent severe disease. The
development of effective vaccines for neonates is particularly chal-
lenging, for many reasons. Passively received antibodies from the
mother, while providing protection against infection, can impair
responses to vaccine antigens, perhaps by sequestering antigen and
effectively reducing the antigenic load, or by masking the relevant
protective epitopes from the B cell receptor, leading to the gener-
ation of antibody responses to sub-optimal epitopes (111, 112).
This may be one reason for a low antibody production to RSV
in neonates and there is some evidence of a reciprocal relation-
ship between maternally derived serum IgG and the production
of nasal sIgA in the neonate following primary infection (108).
The immaturity of the neonatal immune system means that
even in the absence of any interference by maternal antibody,
responses to vaccines are often weak, inappropriately polarized
and short-lived (113, 114). Measles, like RSV, is a paramyxovirus
spread through the respiratory tract, which can cause severe dis-
ease in infants, but for which there is an effective vaccine. Even
in the absence of passively acquired antibodies, measles vaccina-
tion resulted in significantly lower neutralizing antibody titer in
infants below 6 months of age compared to those 9 months old
and above, with only 36% of infants of 6 months old achieving
protective titers, compared to 100% of older infants (115, 116).
This indicates that even once an effective vaccine is developed, the
immaturity of the neonatal immune system itself is a barrier to
generation of protective immunity.
A protective vaccine for neonates will need to overcome the
intrinsic differences in neonatal B cells, as well as providing ade-
quate and appropriate T cell help for the B cells to become activated
(117). Studies of splenic B cells in mice and blood B cells in human
neonates reveal reduced expression of co-stimulatory molecules,
CD40, CD80, and CD86 and TACI (transmembrane activator and
calcium-modulating cyclophilin-ligand interactor), the receptor
for the B cell activating factors BAFF and APRIL (118, 119). The
germinal centers, which promote the activation and maturation
of the antibody response, are poorly developed in neonates, and
production of components of the complement system, is dramat-
ically lower (120). Furthermore, neonatal B cells respond poorly
to IL-4, due to a lack of expression of the receptor alpha chain
(121). Once they have developed, antigen specific B cell responses
decline rapidly, likely because of the lack of B cell survival signals
in the bone marrow (120, 122). Infection of neonatal mice recapit-
ulates the weaker antibody response to RSV infection seen in man.
Here, IFN-γ produced from NK cells or T cells may act to inhibit
the antibody response (123). Therefore, paradoxically too strong a
production of certain cytokines could have detrimental effects by
reducing the amount of antibody produced in neonates. Impor-
tantly, murine studies have found that T follicular helper (Tfh) cell
maturation and numbers are lower in neonates, leading to impair-
ment in the T cell help needed to support the B cell response (124).
Induction of an appropriate, protective T cell response will be key
to the success of a neonatal RSV vaccine.
NEONATAL T CELL RESPONSE TO RSV
Development of a T cell response is necessary to provide the help
for protective antibody production, and to promote viral clear-
ance, but an unbalanced and dysregulated T cell response to RSV
can cause pathology (125). Certainly, those with deficiencies in
the T cell response, including primary deficiencies and HIV infec-
tion, develop more severe disease following infection (17, 126).
In murine models of primary RSV infection, pathology correlates
with the peak of the lymphocyte response in the lungs and CD8+
lymphocytes are required for viral clearance (127–129). In man,
T cells may contribute to the inflammation seen in the lungs in
bronchiolitis, however, a paucity of T cells in the lung was reported
in one study of children who had died of severe RSV disease (34).
The nature, rather than the extent, of T cell responses, and the
resultant balance of viral clearance and immunopathology, may
be key to determining the outcome of RSV infection.
In primary RSV infection in man and mouse, a type-I response
develops, with NK cells, Th1 cells, and CTL all acting as important
sources of IFNγ. In the BALB/c murine model, CD8+ CTL
responses are needed for viral clearance, however, the CD8+
response can also lead to enhanced disease (127, 128). A robust
systemic and local CD8+ T cell response was reported in bron-
chiolitis, but the response was associated with recovery and not
the peak of illness (130, 131). Interestingly, murine studies have
revealed that the epitope dominance of the CD8+ T cell response
differs in RSV infected neonates compared to adults, which may
be mediated by profound differences in the DC populations found
in the neonatal lung, and suggests the CTL response to infection
and vaccination in infants cannot necessarily be predicted from
adult studies (72, 132). Furthermore, epitope specific patterns of
CTL responses set in infancy could persist into adulthood, with
implications for the timing of vaccination.
Although implicated in pathogenic responses to the FI-RSV
vaccine, the relevance of Th2 responses in naturally occurring
RSV disease is unclear. In infants, an imbalance in the ratio of Th1
and Th2 cytokines in nasal lavage, and a low IFNγ response in
BAL and PBMC have been associated with more severe RSV infec-
tion (133–135) and IL-4 was particularly elevated in the youngest
infants (136). Furthermore, children whose cord blood mono-
cytes were less able to produce IFNγ in response to RSV had an
increased frequency of upper respiratory tract infections and res-
piratory related hospitalizations (137). The presence of elevated
concentrations of eosinophil cationic protein has been reported
in bronchiolitis, suggesting a polarized type-2 response (136).
There are a number of experimental circumstances under
which RSV challenge can, unusually for a viral infection, give rise
to Th2-biased lung pathology. Priming with the FI-RSV vaccine
or with RSV G-protein expressed in recombinant vaccinia virus,

























































Lambert et al. Early-life immunity to RSV
leads to enhanced Th2 driven inflammation upon re-infection
(138–140) and infection in IFNγ deficient mice or depletion of
NK cells, a primary source of IFNγ, leads to generation of type-2
inflammation to RSV infection (74, 141). Neonatal RSV infec-
tion in mice leads to the generation of a type-2 response upon
re-challenge in adults (142). Early-life RSV infection may result
in a Th2-biased memory and some studies have found a higher
proportion of peripheral blood IL-4 secreting RSV-specific T cells
following bronchiolitis (143–145), in the absence of an overall bias
of PBMC toward Th2 responses (146). However, others find that
severe RSV is associated with an exuberant non-eosinophilic, lym-
phocytic, and neutrophilic response, or by a lack of inflammatory
response (31, 33, 34).
Th17 responses have more recently been associated with pathol-
ogy in RSV. IL-17, the Th17 promoting cytokines IL-1β, IL-6, and
IL-23, and CD161+ Th17 cells were found to be elevated in the tra-
cheal aspirate of RSV infected infants and IL-17+ CD4+ cells were
elevated in peripheral blood (147–149). In adult mouse models,
IL-17, IL-6, and IL-23 are detected in the airways following infec-
tion and IL-17 promotes neutrophilic lung inflammation, IL-13
production and a mucogenic response to RSV, and inhibits the
CTL response (149–151). Mice deficient in STAT1, which medi-
ates signaling via IFNs, develop elevated IL-23, Th17 and mucus
responses, suggesting that an early, strong IFN response, which
may be lacking in neonates, can reduce the extent of Th17 induc-
tion in RSV (151). Furthermore, mice lacking the cytokine IL-27,
which promotes Th1 development via STAT1 signaling, also devel-
oped elevated Th2 and Th17 responses (152). The Th17 response
was also elevated in the absence of TLR7, perhaps because of a lack
of an IL-12 driven Th1 response (46, 150). IL-17 production by
Th cells was also enhanced in the absence of CCR7 (153).
Together this literature suggests the absence of sufficiently
strong polarization of T cells toward Th1 may allow the emergence
of dysregulated Th17 and Th2 responses to RSV. The neona-
tal immune system provides such an environment in which Th1
responses are weak and Th2 and Th17 responses are promoted.
Neonatal immunization with model antigens tends to give rise to
a Th2 memory response (113, 114, 154, 155). As discussed ear-
lier, neonatal DC production of IL-12 in response to TLR ligands,
which would promote Th1 responses, is substantially reduced in
neonates [reviewed in Ref. (156)]. Interestingly, in neonatal cord
blood monocytes, TLR stimulation produced low amounts of
IL-12 and IFNα, but substantially enhanced levels of the Th17
promoting IL-1, IL-6, and IL-23 (47, 157) and in peripheral blood
monocyte derived DCs, TLR-4, and TLR7 ligands stimulate pro-
duction of Th17 polarizing cytokines in infant, but not adult DC
(148). The production of Th17 promoting cytokines (IL-6 and IL-
23) by peripheral blood monocytes peaks at birth and then declines
over the first few years of life, whereas, the IL-12 and IFNα produc-
tion increase with age, with IL-12 not yet reaching adult levels at
2 years (158). In response to RSV itself neonatal cord blood DC in
co-culture with autologous T cells produced more IL-4, IL-6, IL-1,
and IL-17 and less IL-12p70 and IFNγ than adults, and TGFβ1 was
implicated in mediating this difference (159). TGFβ is expressed
at high levels in the neonatal lung and it will be important to know
how responses of resident lung APC relate to findings in peripheral
blood cells. In conclusion, the T cell priming environment in the
neonate is likely to favor development of potentially pathogenic T
cell responses. Severity, inflammatory context and age at primary
RSV infection may all influence this and set the T cell memory to
RSV early in life.
Regulatory T cells may be key to providing a balanced T cell
response to RSV. In murine models, their depletion leads to
enhanced pathology and the generation of Th2 responses (160,
161). In the murine FI-RSV model, inoculation of chemokines
into the lung to attract regulatory T cells, was able to reduce
severe lung inflammation (101). Circulating levels of regulatory
T cells are lower in children with bronchiolitis, although whether
this represents a selective recruitment to the airways or a lack of
a functional regulatory population is not clear (162). In murine
models, lack of IL-10 leads to enhanced pathology in RSV infection
(163, 164). IL-10 is found in the airways of bronchiolitic children,
is associated with the development of post-bronchiolitic wheeze
(PBW), and IL-10 promoter polymorphisms are associated with
severe RSV disease in infants (133, 165, 166).
Any future neonatal RSV vaccine will need to use appropri-
ate adjuvants to overcome the neonatal Th2 and Th17 bias and
generate appropriate, balanced, protective T cell memory to pro-
vide help for the generation of high affinity, high titer antibody in
the respiratory tract. Under appropriate conditions, neonates can
generate “adult-like” T cell responses, for example at low antigen
loads or with a strong Th1 promoting adjuvant (114, 167–169)
and recently it has been shown that appropriate use of adjuvants
can overcome the impaired Tfh response and boost the genera-
tion of the antibody response in neonates (124). Further, although
vaccination in early-life results in a poor antibody response there
may still be value in vaccinating at this age as a primed adaptive
response can subsequently be boosted to generate effective immu-
nity (117). Multiple doses of vaccine using a prime-boost strategy
may be a successful approach to inducing immunity to RSV at an
early age, although this may be practically and immunologically
challenging given the need to achieve protection within the first
few months of life.
DELAYED SEQUELAE OF RSV BRONCHIOLITIS
The morbidity burden of RSV infection of infants does not solely
encompass the acute disease; for several decades an association
has been reported between early-life RSV bronchiolitis and sub-
sequent persistent wheeze (170). This link has been confirmed
in several large prospective longitudinal studies (146, 171–175).
Sigurs and colleagues have followed 47 children hospitalized for
RSV LRTI at under 1 year of age and so far report an association
with asthma, recurrent wheeze, and also allergic sensitization per-
sisting to age 18 (175–178). In the Tucson Children’s Respiratory
Study, Stein et al. followed children who experienced RSV LRTI
before the age of three and found that the RSV cohort were four
times more likely to report frequent wheeze than controls by age
six (172). In contrast to the Sigurs study, the increased risk attrib-
uted to RSV had diminished by age 13 and no association with
allergy was found, however in the Tucson cohort the RSV cases
were milder LRTI infections with no hospitalization.
There is growing evidence that this association is causal. Wu
et al. demonstrated that the risk of asthma in later childhood was
related to the age of the child (and thus susceptibility to RSV
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infection) at the peak of RSV reason (179). Some of the strongest
evidence for a causal link comes from a recent well-controlled,
randomized, double-blinded trial, in which preventing RSV bron-
chiolitis by administration of palivizumab to preterm infants was
protective against recurrent wheeze in the first year of life (180).
Similar protective effects of palivizumab have been observed to
three (181) and five (182) years of age, suggesting that an early-
life RSV bronchiolitis can indeed have a continuing causal impact
beyond infant infection.
Not all infants who experience bronchiolitis will go on to
develop asthma or post-bronchiolitic wheeze (PBW) and some
infants may be pre-disposed to develop both. Such predisposi-
tion may be apparent before RSV infection. In the Copenhagen
Prospective Study of Asthma in Childhood (COPSAC) birth
cohort of children with family asthma, Chawes et al. reported
that the lungs of neonates who went on to develop bronchiolitis
already exhibited bronchial hyperresponsiveness prior to any viral
infection (183). A recent twin study in Denmark concluded that
severe RSV bronchiolitis was a marker for genetic predisposition to
asthma (184). Furthermore, a genetic polymorphism in the gene
encoding IκBα, a negative regulator of NF-κB, was recently identi-
fied to be associated with both RSV and asthma (30). In addition,
Gern et al. showed that infants whose cord blood responded with
a stronger IFN-γ secretion to RSV stimulation had reduced risk
of early PBW, although the infants in this study were all already at
increased risk of wheeze with an atopic background (185).
POTENTIAL MECHANISMS FOR THE DELAYED SEQUELAE OF RSV
BRONCHIOLITIS
It is not clear how, in those children that are susceptible, RSV
bronchiolitis can lead to the development of PBW. A polymor-
phism in the IL-8 promoter was found at increased prevalence
in children who went on to wheeze following bronchiolitis com-
pared to those who did not, suggesting an inherited predisposition
to delayed sequelae is linked to differential chemokine expression
(186). Ermers and colleagues compared the convalescent blood
monocyte cytokine production following infant RSV bronchioli-
tis and found that high IL-10 and low IL-12 production predicted
increased risk of subsequent wheeze (187). However, this predic-
tion extended only to early (up to age 3 years) and not late (to
6 years) PBW, which the study indicated were two separate disease
entities.
Because of the difficulty in interpreting clinical studies, inves-
tigators have employed animal models to interrogate the effect of
an early-life RSV infection on later airway morbidity. One sug-
gested mechanism is that a viral infection in the context of the
more Th2-skewed neonatal immune system leads to a permanently
dysregulated immune response. In order to probe the interaction
between RSV infection and sensitization to allergens, murine RSV
infection has been combined with models of allergic asthma. The
Th2-biased inflammation and AHR induced by sensitization and
challenge with OVA or cockroach allergen was exacerbated when
preceded by RSV weeks earlier (188, 189). Whilst these studies were
on adult mice, they illustrate an ability of the virus to exacerbate a
Th2 response.
We subsequently established that when mice are primed with an
RSV infection during a critical neonatal window, there is enhanced
“asthma-like”airway inflammation including Th2-biased lympho-
cyte infiltration and eosinophilia when the mice are re-infected as
adults (142). The effect has since been shown to be dependent
on TSLP and IL-13 production and cells of both the adaptive
and innate immune system (141, 190–194). Manipulation of the
immune response during primary infection in the neonate, using
the Th1 promoting cytokine IL-18, CpG or IFNγ, reduces pathol-
ogy following re-infection (141, 195–197). That the outcome of
later disease is determined by the age of the mouse on primary
infection recapitulates the observation in humans that age of RSV
infection and risk of later airway dysfunction are linked (179).
That there is a “critical window” in which an environmental insult
could permanently alter health status – namely, the developmental
origins of health and disease (DoHaD) hypothesis – is an emerging
concept relevant to RSV disease (198).
Perhaps the most faithful model of persistent immunological
effects is a neonatal infection followed by adult challenge with
an unrelated stimulus or allergen. You et al. reported that neona-
tal RSV alone was enough to cause reduced airway function in
adult mice, and when an OVA sensitization/challenge model was
additionally employed, the “allergic” phenotype was exacerbated,
linked to increased IL-13 levels in the BAL (199). Similarly, using
the related pneumovirus of mice (PVM), Siegle found that for
development of all the features of childhood asthma,both neonatal
PVM infection and allergen sensitization/challenge were needed,
dependent on signaling via the IL-4Rα receptor whose ligands
include IL-13 (200). Using a slightly different approach, Krish-
namoorthy et al. employed a model of maternally transferred
tolerance to ovalbumin and observed a breach of tolerance with
induction of an asthma-like state when pups were infected with
RSV (201). In this model, Tregs were implicated in the pathologi-
cal state as they themselves acquired a Th2 phenotype and lost the
ability to suppress inflammation.
Various other mechanisms have been proposed to explain how
RSV might cause long-term airway dysregulation. One controver-
sial theory is that the virus persists or is latent long after the initial
inflammation has cleared. Viral RNA has been found in murine
lung homogenate up to 100 days after RSV infection (202), and
in a guinea pig model persistence of viral RNA correlated with
a chronic AHR (203). It is also plausible that continuous viral
exposure during a critical window during early-life could modu-
late immunological development; however, there is no conclusive
evidence for this hypothesis.
SUMMARY
As protective maternal antibody wanes, the infant immune system
matures and takes over to counter viral infections and to confer
protective immunity. There are still many gaps in our knowledge
of infant immunology and of immunity to RSV infection. We do
not fully understand why in some infants, protection fails and
bronchiolitis develops. The importance of different innate and
adaptive immune mechanisms in protection and pathology are
poorly understood. It is not clear what constitutes a protective
adaptive response to RSV and how to vaccinate to generate it in
infants. To produce a high titer, high affinity antibody response
appropriate T cell help is needed. However, we still do not fully
understand what regulates the differentiation of T cell subsets in
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infants, and how they interact and establish memory. A central
question is why natural B and T cell responses fail to generate
protective immunity to RSV even in adults, and whether this is
determined by host or viral factors.
Much of our understanding of the immunology of infants
has focused on systemic responses or those evident from stud-
ies of cord blood. If sIgA is the optimal form of antibody needed
to protect against infection, then understanding how postnatal
mucosal responses are regulated and develop is an important goal
and may aid the rational design of effective vaccines. Further,
understanding how environmental factors (such as microbiome,
diet, and maternal health) alter the development of the infant
immune response and the outcome of RSV infection may ulti-
mately lessen the burden of bronchiolitis. It seems evident that
success in this arena would not only benefit infants with bronchi-
olitis but would also improve long-term respiratory health in later
life.
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